Orismilast Achieves Early itch Reduction in Adults With AD
Orismilast demonstrated early itch reduction in adults with moderate-to-severe atopic dermatitis (AD), according to a phase 2b study presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Orismilast is a potent selective phosphodiesterase 4 (PDE4)-B and -D inhibitor under development by Union therapeutics. The company is developing orismilast as an […]